Misonix Announces Participation in 2nd International Workshop on Foc...( FARMINGDALE N.Y. June 25 /-Misonix In...),Health

FARMINGDALE, N.Y., June 25 /PRNewswire-FirstCall/ --Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, participated in the 2nd International Workshop on Focal Therapy and Imaging in Prostate and Kidney Cancer, which was held in Noordwijk, The Netherlands, June 10-13, 2009. The meeting was created to address the growing global demand for minimally invasive techniques to ablate urological tumors while maximizing organ preservation. High Intensity Focused Ultrasound and other advanced ablation modalities were featured throughout the program. In addition to the clinical presentations, Misonix exhibited and demonstrated the Sonablate(R) 500 High Intensity Focused Ultrasound ("HIFU") System to the approximately 350 clinicians in attendance.

The Sonablate is a state of the art HIFU instrument used in Europe, Latin America and Asia for trans-rectal ablation of tumors of the prostate gland. Characteristics of HIFU, when used for this purpose, are clinical outcomes similar to other treatment modalities, but with low instances of urinary incontinence and sexual impotence.

The company's SonaTherm HIFU System continues to be utilized in clinical evaluations at the University Hospital, Vienna, Austria, for the ablation of certain lesions of the kidney.

For several years, Sonablate's Visually Directed(TM) HIFU has been successfully used in Europe, in an outpatient setting, for whole gland ablation of prostate carcinoma, with minimal incidences of urinary incontinence and reduced reports of erectile dysfunction. Additional studies for the ablation of unifocal and unilateral prostate disease, while maximizing the preservation of surrounding tissue, are underway at University Col
'/>"/>